First phase III trial of Zactima in NSCLC completes enrollment

Findings from a study suggest that anti-frameshift peptide antibodies may also predict incidence of immune-related adverse effects in patients with lung cancer following immune checkpoint inhibitor therapy.

ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.

“Upon activating a fluorescent lamp, the cancer tissue glows very brightly, like stars against a black sky, and enables us to see exactly where the tumor tissue was.”

Smoking cessation and relapse prevention expert Alan Blum, MD, discusses how oncologists and other clinicians can and should play a larger role in tobacco control.

OncobiotaLUNG, a novel liquid biopsy that detects lung cancer, now has a breakthrough device designation from the FDA.

An expanded indication for pafolacianine as an imaging agent for patients with lung cancer has been approved by the FDA based on findings from the phase 3 ELUCIDATE trial.